Recently, PET/CT room from the First Affiliated Hospital (FAH) of Xi’an Jiaotong University (XJTU) introduced a novel international PET tracer, becoming the first to perform PET/CT imaging for β-amyloid protein in northwest China, which provided potent technical support for prompt diagnosis and precise treatment for patients with Alzheimer's disease (AD). Successful application of this technology by FAH marks a significant step forward in the field of precise diagnosis and treatment of neurodegenerative diseases.

β-amyloid protein is the core biomarker of AD, and its deposition in the brain is intimately correlated with the occurrence and development of AD. Through PET/CT imaging of β-amyloid protein, physicians can intuitively observe abnormal deposition of β-amyloid protein in the brain during the early stage, thereby realizing early identification of AD. In addition, the invention of lecanemab, a targeted therapy drug for β-amyloid protein, brings novel hope to AD patients. Patient screening is a challenge in clinical settings, and PET/CT imaging for β-amyloid protein is the only effective tool.

Since 2013, PET-CT room has introduced the first-generation targeted tracer of β-amyloid protein, cooperated with Department of Neurology to conduct PET/CT imaging for β-amyloid protein for patients with AD and accumulated certain experience in this regard. Successful preparation of the latest-generation targeted tracer of β-amyloid protein further improves diagnostic accuracy, which is worthy of widespread application.